The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

July 1, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial examined the use of nintedanib, a tyrosine kinase inhibitor, in patients with interstitial lung disease (ILD) associated with systemic sclerosis. In the study, these patients had a lower rate of decline in forced vital capacity than those treated with placebo. However, the study did not find the treatment resulted in clinical benefits for other manifestations of systemic sclerosis. The study by Oliver Distler, MD, professor of rheumatology at the University Hospital Zurich, Switzerland, and colleagues was published May 20 in the New England Journal of Medicine.1

You Might Also Like
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
Also By This Author
  • Tracking Bone Deterioration in Patients with Ankylosing Spondylitis

Researchers documented an adverse event profile similar to that seen in the INPULSIS trial of patients with idiopathic pulmonary fibrosis. That said, gastrointestinal adverse events, such as diarrhea, were not only more common in the SENSCIS patient population than in the idiopathic pulmonary fibrosis population, but also more common in nintedanib-treated patients than in placebo-treated patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The large (N=576), randomized, double-blind study included a broad range of patients with ILD-associated systemic sclerosis and extended for one year. Approximately half of the patients had diffuse cutaneous systemic sclerosis and half had limited cutaneous systemic sclerosis. The median time from the onset of the first non-Raynaud’s symptom was 3.4 years, and half of the patients were receiving mycophenolate at baseline.

During the study, patients received at least one dose of nintedanib or placebo, with 80.6% of nintedanib-treated patients and 89.2% of placebo-treated patients completing the 52-week intervention. The primary endpoint was the adjusted annual rate of change in forced vital capacity, which was -52.4 mL per year in the nintedanib group and -93.3 mL per year in the placebo group. The curves in the change from baseline in forced vital capacity separated by Week 12 and continued to diverge. When the investigators performed sensitivity analyses based on multiple imputation for missing data, they calculated P values for the primary endpoint ranging from 0.06 to 0.10.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 52, researchers found no difference between the treatment and placebo groups for the Rodnan skin score, the St. George’s Respiratory Questionnaire (SGRQ), the absolute change from baseline in the score on the Health Assessment Questionnaire-Disability Index (HAQ-DI) or the absolute change from baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnea score. Moreover, pre-specified subgroup analyses revealed the results for the key secondary endpoints did not differ significantly among the patients with different baseline characteristics.

The investigators found no differences between the two groups in the percentages of patients with any adverse event or serious adverse event. The most common adverse event was diarrhea, which was reported in 75.7% of nintedanib-treated patients and 31.6% of placebo-treated patients. Over the entire trial period, 10 nintedanib-treated patients and nine placebo-treated patients died. An uncontrolled, open-label extension study is ongoing.

Pages: 1 2 | Single Page

Filed Under: Conditions

You Might Also Like:
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Interstitial Lung Disease: What Rheumatologists Need to Know

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.